Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
(PDF) Different PSMA Radiopharmaceuticals: A Comparative Study of [18F ...
Comparison of PSMA expression in the present study with various other ...
(PDF) A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate ...
A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer ...
Different PSMA Radiopharmaceuticals: A Comparative Study of [18F]F-PSMA ...
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence ...
PSMA and Beyond 2025: Keynote Lecture: Improving Outcomes with ...
PSMA and Beyond 2025: Overview of Clinical Trials of PSMA RLT in 2025
ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
ASCO 2024: PSMAfore: HRQoL and Pain in a Phase 3 Study of 177Lu-PSMA ...
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the ...
ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA ...
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer ...
SIU 2019: PSMA in Prostate Cancer – Diagnostic to Theranostics
ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with ...
PSMA and Beyond 2025: Can We Kill the Bone Scan?
PSMA Theranostics: Current Landscape and Future Outlook
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a ...
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted ...
ESMO 2024: UpFrontPSMA : A Randomized Phase II Study of Sequential ...
Study to assess combination of MRI and PSMA-PET for prostate cancer ...
EAU 2023: LuTectomy: A Prospective Study of Dosimetry, Safety and ...
A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand ...
Study Comparing Conventional Radiotherapy and PSMA-PET/CT Targeted ...
PSMA targeting in metastatic castration-resistant prostate cancer ...
First-in-human study of PSMA-targeting agent, [F]AlF-P16-093: dosimetry ...
ESMO 2025: What Is next After Clinical Trials Testing PSMA & Lutetium-177?
Figure 1 from A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB ...
Frontiers | Combined biology-guided radiotherapy and Lutetium PSMA ...
Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for ...
(PDF) Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate ...
PSMA and FDG screening. Patient presenting with enlarged liver ...
Tumor Segmentation on PSMA PET/CT Predicts Survival in Biochemical ...
(PDF) An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone ...
Frontiers | Study of predictive factors for response to 177LU-PSMA in ...
ESMO 2022: A Phase 1b Study of a Single Priming Dose of 177Lu-PSMA-617 ...
(PDF) A pilot study of Ga-PSMA-617 PET/CT imaging and Lu-EB-PSMA-617 ...
ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 ...
(PDF) An exploratory study of unexplained concentration of 18F-PSMA ...
A group of normal anterior and posterior planar scintigraphic images of ...
SNMMI 2024: Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive ...
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single ...
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic ...
ESMO 2025: Discussant – Phase III Trial of [177Lu]Lu-PSMA-617 Combined ...
ASCO 2025: PSMA-Targeted Actinium-225 Therapy in Metastatic Castration ...
Frontiers | New Prostate Cancer Targets for Diagnosis, Imaging, and ...
ESMO 2022: Lutetium-177-PSMA Therapy in Patients with Prior Radium-223 ...
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of ...
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved ...
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu ...
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA ...
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with ...
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic ...
Dosimetry of Lutetium-177 PSMA-targeted radiopharmaceutical therapies ...
Examining the Relationship and Prognostic Significance of Cell-Free DNA ...
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic ...
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short ...
Slide 12
ASCO GU 2023: 54: 68Ga-PSMA-11 Patients with Newly Diagnosed and ...
A Review of Theranostics: Perspectives on Emerging Approaches and ...
Frontiers | Case Report: Long-term complete response to PSMA-targeted ...
68Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk ...
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive ...
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model ...
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
Detection of solitary pelvic lymph node metastasis in a patient with ...
(PDF) PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate ...
Figure 1 from Selective Intra-Arterial 177Lu-PSMA Therapy for ...
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy ...
Protocol for SNOTOB study: radical prostatectomy without prostate ...
An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu ...
Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in ...
Prognostic factors of overall and prostate‐specific antigen‐progression ...
ASCO 2025: PSMA-DC: An Open-Label, Multicenter, Randomized Phase 3 ...
PSMA-PET Guided Treatment in Prostate Cancer Patients with ...
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate ...
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate ...
[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic ...
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration ...
PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape ...
An Overview of the Current Treatment Landscape for BPH | Urology Times
177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with ...
(PDF) 177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic ...
Construct design and limitations of select ongoing and completed ...
Key PSMA-Targeting RNT Combination Studies | Download Scientific Diagram
Mechanism of action of lutetium-177-labeled prostate-specific membrane ...
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu ...
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617 ...
(PDF) Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients ...
Summary of 177Lu PSMA-617 studies. | Download Scientific Diagram
Studies about [ 177 Lu]Lu-PSMA-617 in salivary gland carcinoma. IHC ...
Diagnostic Performance of [18F]PSMA-1007 PET/CT on Proven PSMA-Positive ...
(PDF) Comparison of the Efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA ...
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated ...
Belnuc | Positive results presented of the VISION trial - Belnuc
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate ...
Nuclear Medicine Applications in Prostate Cancer | Treatment ...
Summary of 177Lu-PSMA studies. | Download Scientific Diagram
00237-3/asset/791cc06c-708e-4448-9fa7-941f17df1063/main.assets/gr2_lrg.jpg)
